Clinical Trial Detail

NCT ID NCT02971501
Title Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Bevacizumab + Osimertinib

Age Groups: adult senior

No variant requirements are available.